$CDXC $2.84 ChromaDex Responds to Short Attack
Post# of 63821
Posted On: 06/21/2016 7:45:11 AM
$CDXC $2.84
ChromaDex Responds to Short Attack
Website
Shares Outstanding: 37.86M
Float: 27.81M
% Held by Insiders: 41.33%
% Held by Institutions: 0.10%
Headlines
ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company supplies bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. It also provides a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. The companys products and services in development include Nicotinamide riboside, a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene and caffeine co-crystal that are ingredients for the formulation of energy products; and Anthocyanins for application in dietary supplement, sports nutrition, food and beverage, and skin care products. In addition, it is developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, South America, China, Korea, India, Japan, Australia, New Zealand, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is headquartered in Irvine, California.
ChromaDex Responds to Short Attack
Website
Shares Outstanding: 37.86M
Float: 27.81M
% Held by Insiders: 41.33%
% Held by Institutions: 0.10%
Headlines
ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company supplies bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. It also provides a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. The companys products and services in development include Nicotinamide riboside, a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene and caffeine co-crystal that are ingredients for the formulation of energy products; and Anthocyanins for application in dietary supplement, sports nutrition, food and beverage, and skin care products. In addition, it is developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, South America, China, Korea, India, Japan, Australia, New Zealand, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is headquartered in Irvine, California.
(0)
(0)